Aigen Investment Management LP Increases Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Aigen Investment Management LP boosted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 91.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 14,890 shares of the biopharmaceutical company’s stock after buying an additional 7,105 shares during the period. Aigen Investment Management LP’s holdings in Intra-Cellular Therapies were worth $1,090,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Headlands Technologies LLC purchased a new position in shares of Intra-Cellular Therapies during the first quarter valued at approximately $32,000. Summit Securities Group LLC bought a new position in Intra-Cellular Therapies in the 2nd quarter valued at $56,000. Capital Performance Advisors LLP purchased a new stake in Intra-Cellular Therapies in the third quarter worth $74,000. CWM LLC increased its stake in Intra-Cellular Therapies by 83.9% in the second quarter. CWM LLC now owns 1,372 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 626 shares during the period. Finally, Covestor Ltd lifted its position in shares of Intra-Cellular Therapies by 40.4% during the third quarter. Covestor Ltd now owns 1,811 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 521 shares during the last quarter. 92.33% of the stock is currently owned by institutional investors.

Insider Activity

In other Intra-Cellular Therapies news, EVP Mark Neumann sold 18,714 shares of Intra-Cellular Therapies stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the completion of the sale, the executive vice president now owns 29,700 shares of the company’s stock, valued at approximately $2,229,876. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Intra-Cellular Therapies news, EVP Mark Neumann sold 18,714 shares of Intra-Cellular Therapies stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the completion of the sale, the executive vice president now directly owns 29,700 shares in the company, valued at approximately $2,229,876. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Sharon Mates sold 53,013 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at $80,970,388.85. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 175,316 shares of company stock valued at $13,037,345 over the last ninety days. 2.60% of the stock is currently owned by insiders.

Intra-Cellular Therapies Price Performance

Shares of ITCI stock opened at $88.49 on Wednesday. The stock’s fifty day moving average price is $77.45 and its 200 day moving average price is $74.02. Intra-Cellular Therapies, Inc. has a 1-year low of $52.88 and a 1-year high of $93.45. The company has a market cap of $9.38 billion, a price-to-earnings ratio of -101.71 and a beta of 0.97.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $175.40 million during the quarter, compared to analyst estimates of $172.30 million. During the same quarter last year, the business earned ($0.25) earnings per share. The firm’s revenue for the quarter was up 39.0% on a year-over-year basis. As a group, equities research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on ITCI. UBS Group reduced their price target on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Piper Sandler raised shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $68.00 to $92.00 in a research report on Friday, September 6th. Royal Bank of Canada boosted their price target on Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an “outperform” rating in a report on Friday, October 4th. Cantor Fitzgerald restated an “overweight” rating and set a $130.00 price objective on shares of Intra-Cellular Therapies in a report on Monday, September 16th. Finally, Morgan Stanley upped their target price on Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, Intra-Cellular Therapies currently has an average rating of “Moderate Buy” and an average price target of $97.23.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.